Rallybio (RLYB) Expected to Announce Quarterly Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:00 AM ET.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. The business had revenue of $0.21 million for the quarter. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. On average, analysts expect Rallybio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rallybio Price Performance

Rallybio stock opened at $0.63 on Wednesday. The firm’s 50 day simple moving average is $0.58 and its 200-day simple moving average is $0.46. The company has a market cap of $26.31 million, a P/E ratio of -0.67 and a beta of -1.05. Rallybio has a fifty-two week low of $0.22 and a fifty-two week high of $1.24.

Wall Street Analysts Forecast Growth

RLYB has been the topic of several analyst reports. Wall Street Zen downgraded shares of Rallybio from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Rallybio currently has a consensus rating of “Reduce” and an average price target of $5.00.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.